WO1999056766A2 - Traitement de l'ischemie - Google Patents
Traitement de l'ischemie Download PDFInfo
- Publication number
- WO1999056766A2 WO1999056766A2 PCT/US1999/009452 US9909452W WO9956766A2 WO 1999056766 A2 WO1999056766 A2 WO 1999056766A2 US 9909452 W US9909452 W US 9909452W WO 9956766 A2 WO9956766 A2 WO 9956766A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- deltorphin
- administered
- ischemia
- mammal
- seq
- Prior art date
Links
- 208000028867 ischemia Diseases 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 27
- 101800005209 Deltorphin Proteins 0.000 claims abstract description 44
- BHSURCCZOBVHJJ-NWOHMYAQSA-N Deltorphin A Chemical compound C([C@H](N)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)C1=CC=C(O)C=C1 BHSURCCZOBVHJJ-NWOHMYAQSA-N 0.000 claims abstract description 44
- 241000124008 Mammalia Species 0.000 claims abstract description 20
- 230000000302 ischemic effect Effects 0.000 claims abstract description 19
- 230000037396 body weight Effects 0.000 claims abstract description 14
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 14
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 10
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 9
- 108700040992 Ala(2)- deltorphin I Proteins 0.000 claims abstract description 8
- CJAORFIPPWIGPG-QXYJMILXSA-N Deltorphin C Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 CJAORFIPPWIGPG-QXYJMILXSA-N 0.000 claims abstract description 8
- 108700040991 Ala(2)- deltorphin II Proteins 0.000 claims abstract description 5
- NUNBRHVOPFWRRG-RCEFDBTISA-N Deltorphin B Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NUNBRHVOPFWRRG-RCEFDBTISA-N 0.000 claims abstract description 5
- 208000036982 Spinal cord ischaemia Diseases 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims abstract 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000001603 reducing effect Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 description 26
- 210000004556 brain Anatomy 0.000 description 16
- 208000006011 Stroke Diseases 0.000 description 10
- ZHUJMSMQIPIPTF-IBURTVSXSA-N (2r)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-IBURTVSXSA-N 0.000 description 9
- 108010004028 Leucine-2-Alanine Enkephalin Proteins 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000003727 cerebral blood flow Effects 0.000 description 7
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000005189 Embolism Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000007971 neurological deficit Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 201000010849 intracranial embolism Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010002921 Aortitis Diseases 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 208000003890 Coronary Vasospasm Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 201000011634 coronary artery vasospasm Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- CJAORFIPPWIGPG-PKNMDTBHSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 CJAORFIPPWIGPG-PKNMDTBHSA-N 0.000 description 1
- NUNBRHVOPFWRRG-MPNDMYOWSA-N (4s)-4-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NC(C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NUNBRHVOPFWRRG-MPNDMYOWSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000002087 Endarteritis Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067441 Myelomalacia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000269433 Phyllomedusa bicolor Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000012484 Spinal Cord Vascular disease Diseases 0.000 description 1
- 206010048992 Spinal cord haemorrhage Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 238000002585 cerebral angiography Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011961 computed axial tomography Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to the use of deltorphins to treat cerebral
- the decreased blood flow may be due to, for
- an occlusion such as a thrombus or embolus, vessel rupture, sudden
- Atherosclerosis trauma, aneurysm, developmental malformation, altered
- Ischemic necrosis of the spinal cord may result in sensory or motor symptoms or both that can be referred to
- ischemic heart disease the individual suffers angina pectoris, acute myocardial
- the imbalance may be caused by, for example,
- nonatheromatous coronary obstructive lesions such as embolism, coronary
- Drugs are frequently preferred
- the present invention fills this need by providing a method of
- the ischemic tissue may be any tissue that has a deltorphin tc said mammal.
- the ischemic tissue may be any tissue that has a deltorphin tc said mammal.
- the present invention is also directed to a method of reducing the rate of a stroke.
- the present invention is also directed to a method of treating
- the deltorphin is administered in a pharmaceutical
- composition at a dosage in the range of about 0.5 mg/kg body weight to about
- the mammal is a human.
- Deltorphins are endogenous linear heptapeptides isolated from
- Deltorphin I SEQ ID NO:1 has the same amino acid sequence depending on their amino acid sequence.
- Deltorphin II SEQ ID NO:2 has the amino acid sequence
- deltorphin I SEQ ID NO: 1 and II SEQ ID NO:2 may be used in the invention.
- Deltorphins may be obtained from frog skin extracts or may be synthesized using a commercial peptide synthesizer such the type available from Applied
- Deltorphins can be administered to ameliorate or inhibit damage
- a stroke is the acute neurologic injury caused by one of
- pathologic process may be intrinsic to the vessel itself such as in
- arteriosclerosis or may originate from a remote location such as an embolus
- the main causes of ischemic stroke are thrombosis,
- Signs of stroke include paralysis, slurred
- CT computed to the brain.
- deltorphins can be administered to limit injury
- the ideal mode of administration is by intraperitoneal (i.p.) or
- intravenous (i.v.) injection at a dose of about 0.5-20 mg/kg, or alternatively of
- Deltorphins can also be administered by subcutaneous
- cardiac arrhythmias or diseases due to cardiac structural abnormalities may be characterized by cardiac arrhythmias or diseases due to cardiac structural abnormalities
- emboli may result in emboli being produced which can migrate into
- Emboli formation and migration can occur as a result
- microemboli which can migrate into the arteries of the brain and cause a
- Cerebral embolism is also the principal complication in the transplant of
- deltorphins can be administered to prevent brain
- Deltorphins can be administered to ameliorate or prevent ischemic
- the ischemia may be caused by an endarteritis of
- aortic aneurysms may cause infarction of the spinal cord (myelomalacia) by occluding nutrient arteries at cervical, thoracic or lumbar
- vascular lesions of the spinal cord may result in the sudden
- onset of symptoms referable to sensory or motor or both spinal tract lesions.
- Deltorphins can also be administered to ameliorate or inhibit
- Ischemic heart disease is a general
- nonatheromatous coronary obstructive lesions such as embolism, coronary
- ostial stenosis associated with luetic aortitis, coronary artery spasm, or very
- carboxyhemoglobin e.g., due to cigarette
- ischemic events When ischemic events are transient, they may be associated
- Ischemic heart disease may be readily diagnosed by one skilled
- arteriography may also provide diagnostic information. These diagnostic test
- results may determine the need for deltorphin administration.
- ischemic heart disease include a positive family history of ischemic heart disease, diabetes,
- Deltorphins may be administered to asymptomatic individuals
- deltorphins may be administered to
- Deltorphins may be
- nitrates beta-adrenergic blockers
- calcium channel antagonists calcium channel antagonists
- fibrinolytic drugs such as
- tissue plasminogen activator tPA
- streptokinase streptokinase
- urokinase urokinase
- deltorphins may prolong life and/or reduce or eliminate the need for invasive
- deltorphins are administered
- Deltorphins may be formulated for administration in an aqueous
- cyclodextran may be formulated in an organic liquid such as cyclodextran or
- the solution or emulsion may be
- intravenous, intramuscular, intradermal or intraperitoneal injections as by intravenous, intramuscular, intradermal or intraperitoneal injections.
- a preferred deltorphin dose is in the range of about 0.5 mg/kg
- body weight of the mammal to about 20 mg/kg body weight of the mammal
- a single dose of the deltorphin is preferably up to about four hours after onset of an ischemic episode.
- the deltorphin may be administered
- Efficacy of deltorphin treatment may be evaluated using
- noninvasive clinical imaging methods such as magnetic resonance imaging
- Ischemia was induced by transient occlusion of the external
- ECA carotid artery
- LCCA common carotid artery
- STA styrene-maleic anvil (STA)
- OA occipital artery
- the base of the ECA was secured with a
- MABP mean arterial blood pressure
- Test compounds were the delta opioid DADLE (Tyr-D-Ala-Gly-Phe-
- test compound in solution was administered by i.p. injection at a predetermined interval.
- Control animals received i.p. injections of saline or 1 %
- Brain infarct volume was measured after 1 h of ischemia and
- Brain sections were made. Brain sections
- TTC 2,3,5-triphenyltetrazolium chloride
- cerebral blood flow returned to baseline levels within
- MABP MABP, p0 2 , pC0 2 , pH or rectal temperature between control animals and
- deltorphin I SEQ ID NO: 1 deltorphin II SEQ ID NO:2 or a combination of
- deltorphins I SEQ ID NO: 1 and II SEQ ID NO:2 are formulated for
- deltorphin dose may be administered up to four hours after the onset of an
- the deltorphin dose may be administered
- Deltorphin administration reduces the effect of an ischemic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
On traite l'ischémie, dans le cadre de cette invention, en administrant des deltorphines à un mammifère. Il est possible d'administrer la deltorphine I SEQ ID N° 1, la deltorphine II SEQ ID N° 2 ou leur combinaison. On administre, jusqu'à quatre heures après un épisode ischémique, une formulation, acceptable du point de vue physiologique, dont la teneur en deltorphine est comprise entre 0,5 et 20 mg/kg environ ou, selon une variante, entre 1 et 1000 νg par kilo de poids corporel du mammifère. Il est également possible d'administrer des deltorphines avant l'apparition de l'ischémie ou simultanément à celle-ci. On peut traiter avec cette méthode l'ischémie cérébrale, celle de la moelle épinière ou encore la cardiopathie ischémique.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE69902096T DE69902096T2 (de) | 1998-05-01 | 1999-04-30 | Deltorphin zur behandlung von ischemie |
| JP2000546790A JP2003522727A (ja) | 1998-05-01 | 1999-04-30 | 虚血の治療方法 |
| BR9909876-8A BR9909876A (pt) | 1998-05-01 | 1999-04-30 | Composições farmacêuticas para tratamento, melhoria ou prevenção da isquemia, respectivos métodos e usos |
| AU37758/99A AU756200B2 (en) | 1998-05-01 | 1999-04-30 | Method for treating ischemia |
| MXPA00010616A MXPA00010616A (es) | 1998-05-01 | 1999-04-30 | Metodo para tratar isquemia. |
| AT99920203T ATE220330T1 (de) | 1998-05-01 | 1999-04-30 | Deltorphin zur behandlung von ischemie |
| EP99920203A EP1073451B1 (fr) | 1998-05-01 | 1999-04-30 | Traitement de l'ischemie a l'aide de deltorphine |
| NZ507523A NZ507523A (en) | 1998-05-01 | 1999-04-30 | Method for treating ischemia with deltorphin |
| CA002325387A CA2325387A1 (fr) | 1998-05-01 | 1999-04-30 | Traitement de l'ischemie |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7123698A | 1998-05-01 | 1998-05-01 | |
| US09/071,236 | 1998-05-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999056766A2 true WO1999056766A2 (fr) | 1999-11-11 |
| WO1999056766A3 WO1999056766A3 (fr) | 2003-04-17 |
Family
ID=22100105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/009452 WO1999056766A2 (fr) | 1998-05-01 | 1999-04-30 | Traitement de l'ischemie |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1073451B1 (fr) |
| JP (1) | JP2003522727A (fr) |
| AT (1) | ATE220330T1 (fr) |
| AU (1) | AU756200B2 (fr) |
| BR (1) | BR9909876A (fr) |
| CA (1) | CA2325387A1 (fr) |
| DE (1) | DE69902096T2 (fr) |
| MX (1) | MXPA00010616A (fr) |
| NZ (1) | NZ507523A (fr) |
| WO (1) | WO1999056766A2 (fr) |
| ZA (1) | ZA200005920B (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002030450A1 (fr) * | 2000-10-10 | 2002-04-18 | University Of Kentucky Research Foundation | Utilisation de la deltorphine d-leu dans la protection contre les lesions ischemique et de reperfusion |
| WO2002022152A3 (fr) * | 2000-09-12 | 2003-01-23 | Univ Kentucky Res Found | Protection contre les lesions liees a l'ischemie et a la reperfusion |
| US6875742B2 (en) | 2000-10-10 | 2005-04-05 | Zymogenetics, Inc. | Method for treating cytokine mediated hepatic injury |
| US7705119B1 (en) | 2007-04-09 | 2010-04-27 | University Of Kentucky Research Foundation | Compositions and methods useful for treating circulatory and hypovolemic shock |
| US7811992B2 (en) | 2002-02-06 | 2010-10-12 | Stasys Technologies, Inc. | Anti-infarction molecules |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298181B1 (fr) | 2003-10-17 | 2017-04-12 | Covidien LP | Assemblage avec enclume inclinable pour une agrafeuse chirurgicale |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656420A (en) * | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
-
1999
- 1999-04-30 AU AU37758/99A patent/AU756200B2/en not_active Ceased
- 1999-04-30 AT AT99920203T patent/ATE220330T1/de not_active IP Right Cessation
- 1999-04-30 DE DE69902096T patent/DE69902096T2/de not_active Expired - Fee Related
- 1999-04-30 NZ NZ507523A patent/NZ507523A/xx unknown
- 1999-04-30 CA CA002325387A patent/CA2325387A1/fr not_active Abandoned
- 1999-04-30 MX MXPA00010616A patent/MXPA00010616A/es unknown
- 1999-04-30 BR BR9909876-8A patent/BR9909876A/pt not_active Application Discontinuation
- 1999-04-30 WO PCT/US1999/009452 patent/WO1999056766A2/fr active IP Right Grant
- 1999-04-30 JP JP2000546790A patent/JP2003522727A/ja active Pending
- 1999-04-30 EP EP99920203A patent/EP1073451B1/fr not_active Expired - Lifetime
-
2000
- 2000-10-23 ZA ZA200005920A patent/ZA200005920B/en unknown
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022152A3 (fr) * | 2000-09-12 | 2003-01-23 | Univ Kentucky Res Found | Protection contre les lesions liees a l'ischemie et a la reperfusion |
| US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| US7060792B2 (en) | 2000-09-12 | 2006-06-13 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| WO2002030450A1 (fr) * | 2000-10-10 | 2002-04-18 | University Of Kentucky Research Foundation | Utilisation de la deltorphine d-leu dans la protection contre les lesions ischemique et de reperfusion |
| US6645938B2 (en) | 2000-10-10 | 2003-11-11 | Zymogenetics, Inc. | Protection against ischemia and reperfusion injury |
| US6875742B2 (en) | 2000-10-10 | 2005-04-05 | Zymogenetics, Inc. | Method for treating cytokine mediated hepatic injury |
| US7335642B2 (en) | 2000-10-10 | 2008-02-26 | University Of Kentucky Research Foundation | Method for treating a viral infection related or a chemical toxin related hepatic injury with deltorphin D |
| US7811992B2 (en) | 2002-02-06 | 2010-10-12 | Stasys Technologies, Inc. | Anti-infarction molecules |
| US7705119B1 (en) | 2007-04-09 | 2010-04-27 | University Of Kentucky Research Foundation | Compositions and methods useful for treating circulatory and hypovolemic shock |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9909876A (pt) | 2000-12-19 |
| NZ507523A (en) | 2002-09-27 |
| DE69902096T2 (de) | 2003-02-27 |
| EP1073451B1 (fr) | 2002-07-10 |
| ATE220330T1 (de) | 2002-07-15 |
| ZA200005920B (en) | 2003-03-05 |
| WO1999056766A3 (fr) | 2003-04-17 |
| AU756200B2 (en) | 2003-01-09 |
| JP2003522727A (ja) | 2003-07-29 |
| AU3775899A (en) | 1999-11-23 |
| EP1073451A3 (fr) | 2003-06-04 |
| CA2325387A1 (fr) | 1999-11-11 |
| EP1073451A2 (fr) | 2001-02-07 |
| DE69902096D1 (de) | 2002-08-14 |
| MXPA00010616A (es) | 2002-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7143374B2 (ja) | 虚血のための組み合わせ療法 | |
| Sehba et al. | The importance of early brain injury after subarachnoid hemorrhage | |
| Palmon et al. | Venous air embolism: a review | |
| JP2921870B2 (ja) | 製 剤 | |
| Karhunen et al. | Adverse reactions to fluorescein angiography | |
| US6544950B1 (en) | Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury | |
| JP2018052962A (ja) | くも膜下出血および虚血の治療法 | |
| US6294519B1 (en) | Method for treating ischemia | |
| EP1073451B1 (fr) | Traitement de l'ischemie a l'aide de deltorphine | |
| JPH05501856A (ja) | 脳及び筋肉組織傷害による浮腫の治療剤 | |
| KR20230141958A (ko) | 개선된 치료 지수를 위한 플라스민-내성 펩티드 | |
| CA2304956C (fr) | Agents preventifs ou remedes pour les maladies ischemiques | |
| Morgan et al. | Outcome of aneurysmal subarachnoid haemorrhage following the introduction of papaverine angioplasty | |
| Oeltgen et al. | Method for treating ischemia | |
| Freeman et al. | Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhagic shock in cats. | |
| US8106009B2 (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
| JP5870369B2 (ja) | 血液脳関門障害改善剤 | |
| Sweid et al. | Endovascular neurosurgery | |
| KR20100089077A (ko) | 혈전용해를 위한 신규한 환자 소집단 | |
| Hess et al. | Digoxin-specific antibody fragments and a calcium antagonist for reversal of digoxin-induced mesenteric vasoconstriction | |
| AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
| WO2006022281A1 (fr) | Traitements prophylactique et thérapeutique de la perturbation des métabolismes du collagène ou de l’élastine | |
| Kam et al. | The pharmacology of ornipressin (POR–8): a local vasoconstrictor used in surgery | |
| BONNIN et al. | Hyponatraemia and renovascular hypertension: case report with plasma renin and vascular sensitivity studies | |
| JP2001514629A (ja) | 薬剤製造へのヒトα▲下１▼−酸性糖蛋白質の使用法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 507523 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 37758/99 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2325387 Country of ref document: CA Ref country code: CA Ref document number: 2325387 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999920203 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000/05920 Country of ref document: ZA Ref document number: 200005920 Country of ref document: ZA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/010616 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 546790 Kind code of ref document: A Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999920203 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1999920203 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 37758/99 Country of ref document: AU |